Clin2
NCT07083193Possibly a fitRecruiting

Study of AC-101 tablets for moderate to severe ulcerative colitis

Ulcerative Colitis

Part of Digestive system clinical trials.

This trial tests a new tablet called AC-101 for people with active moderate to severe ulcerative colitis. It aims to see if the drug can reduce symptoms like diarrhea and bleeding and help the gut heal.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
24 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You must have ulcerative colitis diagnosed at least 3 months ago and confirmed by a scope and biopsy.
  • Your disease must be active, with a Mayo score of 5 to 9, meaning moderate symptoms like frequent stools and bleeding.
  • The inflammation in your colon must extend at least 6 inches from the anal opening.
  • You must be on stable doses of 5-ASA or oral steroids (like prednisone ≤20 mg/day) for 2 weeks before starting.
  • You can be new to biologics or have been off them for at least 5 half-lives.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07265570Recruiting· Phase 2
ISM5411 for active ulcerative colitis

This trial tests an experimental drug (ISM5411) for people with active ulcerative colitis. The goal is to see if the drug can reduce inflammation and improve symptoms.

Beijing, Beijing Municipality
NCT06420375Recruiting· Phase 2
New treatment for active ulcerative colitis

This trial tests a new treatment for people with ulcerative colitis (UC) whose disease is active despite taking only mesalamine or sulfasalazine. It aims to find a therapy that can reduce inflammation and improve symptoms.

Chestnut Hill, Massachusetts
NCT06636656Recruiting· Phase 2
Testing a new drug for ulcerative colitis after other treatments failed

This study tests a new medication called BI 3032950 for people with ulcerative colitis who have already tried other advanced treatments (biologics or targeted therapies) that didn't work well enough or caused problems. The goal is to see if the new drug is safe and helps control inflammation in the colon.

Scottsdale, Arizona
NCT07692165Recruiting· Phase 1/Phase 2
Testing INT-210 capsules for active ulcerative colitis

This trial tests an experimental capsule called INT-210 for people with active ulcerative colitis (UC) who haven't improved enough with standard treatments. It aims to see if the drug can help control symptoms and improve the condition.

Guangzhou, Guangdong
NCT07650942Not yet recruiting· Phase 3
Hemay005 treatment for moderate to severe ulcerative colitis

This study tests whether a new drug called Hemay005 can help people with moderate to severe ulcerative colitis (a chronic bowel condition causing inflammation and symptoms like diarrhea and abdominal pain) who haven't responded well to or can't tolerate standard treatments. The goal is to reduce inflammation and improve symptoms.

Guangzhou
NCT07755241Not yet recruiting· Phase 2
AC-101 tablets for ulcerative colitis

This trial tests an oral tablet called AC-101 for people with moderate to severe ulcerative colitis. It aims to see if the drug can reduce inflammation in the colon and improve symptoms.

Hear when a new Ulcerative Colitis trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.